Redeye Initiates Coverage of Ultimovacs
2022-04-04 07:45:00
Redeye initiates coverage of Ultimovacs, a Nordic biotech company developing therapeutic cancer vaccines, which we believe has delivered promising phase I efficacy data in malignant melanoma. We view the current share price as an attractive entry opportunity for long-term-oriented investors.
Read more and download the Research Report.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/